Table 1 Effect of thalidomide and analogs on cytokine production by LPS-stimulated human monocytes
From: Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity
Compound (conc) | Cytokine Levels | ||||
|---|---|---|---|---|---|
TNFα | GM-CSF | IL-1β | IL-6 | IL-10 | |
LPS (1 µg/ml) +: | |||||
0.25% DMSO (control) | 6.1 ± 2.0 ng/ml | 0.4 ± 0.4 ng/ml | 23.8 ± 7.0 ng/ml | 540 ± 11 ng/ml | 1.9 ± 1.1 ng/ml |
Thalidomide (194 µM) | 49 ± 4.0%a,b | 86 ± 5.50% | 86 ± 20.3% | 100 ± 13.5% | 149 ± 26.0%b |
CC-1069 (12.5 µM) | 40 ± 5.9%b | 56 ± 1.50%b | 77 ± 4.60%b | 97 ± 5.60% | 130 ± 16.4% |
CC-1104 (2.7 µM) | 50 ± 8.6%b | 62 ± 13.9% | 91 ± 13.9% | 88 ± 7.00% | 140 ± 21.8% |
CC-1115 (0.5 µM) | 44 ± 8.9%b | 25 ± 0.90%b | 99 ± 10.9% | 102 ± 8.60% | 160 ± 14.9%b |